消癌平注射液联合化疗治疗晚期非小细胞肺癌的Meta分析
|
摘要
[目的]本研究旨在从循证医学角度系统评价消癌平注射液联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。[方法]计算机检索截止至2018年5月已经发表在Cochrane Library、PubMed、EMBASE、中国期刊全文数据库(CNKI)、万方期刊数据库、维普资讯中文期刊服务平台(VIP)中的文献,纳入消癌平注射液联合化疗治疗NSCLC的临床随机对照试验。对纳入的研究采用"偏倚风险评估工具"进行文献质量评价。提取研究特征、方法和结果的数据,运用Review Manager 5.3软件进行分析,并检验发表偏倚。[结果]共纳入文献26篇,病例1 783例。结果显示,与单纯化疗组相比,消癌平注射液联合化疗能提高治疗的总有效率[RR=1.30,95%CI(1.16,1.46),P<0.000 01]、疾病控制率[RR=1.17,95%CI(1.10,1.23),P<0.000 01)]、生活质量[RR=2.16,95%CI(1.80,2.61),P<0.000 01],并能减少不良反应的发生。[结论]消癌平注射液能提高晚期NSCLC患者化疗疗效,改善生活质量,减轻不良反应。
[Objective] This study systematically evaluated the clinical efficacy and adverse reactions of Xiaoaiping Injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC) from the perspective of evidence-based medicine.[Methods] The literatures as of May 2018 were published in the Cochrane Library,PubMed,EMBASE,CNKI,Wanfang data,and VIP.The randomized controlled trial of Xiaoaiping injection combined with chemotherapy in the treatment of non-small cell lung cancer was included. For the included studies,the "The Cochrane Collaboration's tool for assessing risk of bias" was used for literature quality evaluation. Data on study characteristics,methods,and results were extracted,analyzed using RevMan 5.3,and published bias was examined. [Results] A total of 26 articles were included,and a total of 1 783 cases were included. As a result,compared with the chemotherapy alone group,Xiaoaiping Injection combined with chemotherapy can improve the total effective rate of patients(RR =1.30,95%CI[1.16,1.46],P<0.000 01),disease control rate(RR=1.17,95%CI[1.10,1.23],P<0.000 01),quality of life(RR=2.16,95%CI [1.80,2.61],P <0.00001),and reduced the occurrence of adverse reactions. [Conclusion] Xiaoaiping Injection can improve the efficacy of chemotherapy in patients with advanced non-small cell lung cancer,improve the quality of life and reduce adverse reactions.
[Objective] This study systematically evaluated the clinical efficacy and adverse reactions of Xiaoaiping Injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC) from the perspective of evidence-based medicine.[Methods] The literatures as of May 2018 were published in the Cochrane Library,PubMed,EMBASE,CNKI,Wanfang data,and VIP.The randomized controlled trial of Xiaoaiping injection combined with chemotherapy in the treatment of non-small cell lung cancer was included. For the included studies,the "The Cochrane Collaboration's tool for assessing risk of bias" was used for literature quality evaluation. Data on study characteristics,methods,and results were extracted,analyzed using RevMan 5.3,and published bias was examined. [Results] A total of 26 articles were included,and a total of 1 783 cases were included. As a result,compared with the chemotherapy alone group,Xiaoaiping Injection combined with chemotherapy can improve the total effective rate of patients(RR =1.30,95%CI[1.16,1.46],P<0.000 01),disease control rate(RR=1.17,95%CI[1.10,1.23],P<0.000 01),quality of life(RR=2.16,95%CI [1.80,2.61],P <0.00001),and reduced the occurrence of adverse reactions. [Conclusion] Xiaoaiping Injection can improve the efficacy of chemotherapy in patients with advanced non-small cell lung cancer,improve the quality of life and reduce adverse reactions.
引文
[1]董南.多西紫杉醇联合消癌平注射液二线治疗晚期NSCLC的效果分析[J].中国实用医药,2015,10(5):140-141.
[2]王帅兵,刘威威,齐秀恒,等.多西紫杉醇联合消癌平注射液二线治疗晚期非小细胞肺癌的临床观察[J].现代中西医结合杂志,2013,22(30):3334-3336.
[3]吴宏林.多西紫杉醇联合消癌平注射液二线治疗晚期非小细胞肺癌的效果评价[J].中国医药指南,2016,14(15):171-172.
[4]张志华,张海冬.培美曲塞联合消癌平注射液治疗中晚期非小细胞肺癌32例临床疗效观察[J].中国医药指南,2012,10(12):553-554.
[5]赵伟.消癌平联合多西紫杉醇治疗晚期非小细胞肺癌的疗效研究[J].心理医生,2017,23(2):65-66.
[6]李心国,姜晓静.消癌平注射液联合GP方案治疗晚期非小细胞肺癌的临床观察[J].中国临床医生杂志,2016,44(10):62-64.
[7]王延涛.消癌平注射液联合GP方案治疗晚期非小细胞肺癌的临床研究[J].青岛医药卫生,2012,44(4):246-248.
[8]张丰云,李秋文,管静芝,等.消癌平注射液联合GP方案治疗晚期非小细胞肺癌疗效观察[J].肿瘤基础与临床,2011,24(5):415-417.
[9]李清林,程斌.消癌平注射液联合GP化疗方案治疗晚期非小细胞肺癌临床疗效研究[J].中华中医药学刊,2016,34(4):785-787.
[10]杨宏,吕爽,王珏,等.消癌平注射液联合NP方案治疗晚期NSCLC的临床观察[J].中国医药导报,2011,8(8):64-65.
[11]高志豪.消癌平注射液联合TC方案治疗非小细胞肺癌晚期患者的疗效观察[J].当代医学,2016,22(25):153-154.
[12]李亚莉,周恒根,倪敬忠,等.消癌平注射液联合TC方案治疗晚期非小细胞肺癌临床观察[J].现代中西医结合杂志,2015,24(3):316-318.
[13]梅朝蓉,王恳,雷娜,等.消癌平注射液联合TP方案治疗晚期非小细胞肺癌的临床观察[J].中国药房,2015,24(11):1531-1533.
[14]夏国安.消癌平注射液联合TP方案治疗晚期非小细胞肺癌临床观察[J].临床医药实践,2013,22(2):83-85.
[15]沈李伟,邱文生,兰传鑫,等.消癌平注射液联合TP化疗治疗晚期非小细胞肺癌疗效观察[J].中外医学研究,2015,13(32):8-9.
[16]刘爱芳.消癌平注射液联合化疗治疗晚期非小细胞肺癌的疗效体会[J].临床医药文献电子杂志,2016,3(22):4415-4416.
[17]方欢,王静,潘春峰,等.消癌平注射液联合化疗治疗晚期非小细胞肺癌的临床观察[J].中国医院用药评价与分析,2013,13(2):165-168.
[18]张瑞星,岳江涛,王天平,等.消癌平注射液联合化疗治疗晚期非小细胞肺癌的临床观察[J].肿瘤基础与临床,2012,25(5):438-440.
[19]姜子瑜,李灵常.消癌平注射液联合化疗治疗晚期非小细胞肺癌临床分析[J].内蒙古中医药,2017,36(23):100-101.
[20]宋宇,钱晓兰,王少开,等.消癌平注射液联合化疗治疗晚期非小细胞肺癌临床疗效评价[J].中医临床研究,2016,8(36):122-123.
[21]石磊,杨卫兵,柏玉举,等.消癌平注射液联合化疗治疗中晚期肺癌的临床分析[J].医药前沿,2015,5(26):155-156.
[22]徐建建.消癌平注射液联合化疗治疗中晚期肺癌的临床分析[J].中外医疗,2017,36(12):116-118.
[23]胡晓琳,刘喜松,陈细定.消癌平注射液联合吉西他滨和卡铂治疗ⅢB和Ⅳ期非小细胞肺癌的临床评价[J].药物评价研究,2017,40(2):262-265.
[24]朱丹.消癌平注射液联合间断化疗对老年晚期非小细胞肺癌的治疗效果观察[J].中国医药指南,2017,15(36):206-207.
[25]杨万全,王恳.消癌平注射液联合间断化疗治疗老年晚期非小细胞肺癌[J].肿瘤基础与临床,2013,26(6):495-497.
[26]瞿红英.多西紫杉醇联合消癌平注射液二线治疗晚期NSCLC的疗效观察[J].世界最新医学信息文摘,2015,15(A5):11-12.
[27]Siegel RL,Miller KD,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
[28]石远凯,孙燕,丁翠敏,等.中国埃克替尼治疗非小细胞肺癌专家共识(2016年版)[J].中国肺癌杂志,2016,19(7):489-494.
[29]国家药典委员会.中华人民共和国药典[M].北京:中国医药科技出版社,2015:296-297.
[30]白爽,李奕诺,徐鑫,等.乌骨藤化学成分及药理活性研究进展[J].解放军药学学报,2015,31(3):260-264.
[31]杨洪枢,张科军,宋程浩,等.消癌平注射液对原发性肝癌术前患者机体免疫功能的影响[J].中华中医药学刊,2015,33(6):1438-1440.
[32]韩淑燕,郑文献,何曦冉,等.消癌平注射液联合吉非替尼对耐药非小细胞肺癌H460和H1975裸鼠移植瘤的抑制作用[J].中国药理学与毒理学杂志,2016,30(1):44-52.
[33]郑爱文,李涛,陈雅卿,等.消癌平联合顺铂对高转移人卵巢癌HO-8910PM细胞的抑制作用[J].中华肿瘤杂志,2016,38(1):11-16.
[34]王美,杜丹玉,范薇,等.消癌平注射液抗血管生成作用及其机制研究[J].药学学报,2016,51(2):309-315.
[35]王峰,樊青霞,王洪海,等.消癌平注射液联合化疗治疗中晚期食管癌的疗效和安全性[J].中华肿瘤杂志,2017,39(6):453-457.
[2]王帅兵,刘威威,齐秀恒,等.多西紫杉醇联合消癌平注射液二线治疗晚期非小细胞肺癌的临床观察[J].现代中西医结合杂志,2013,22(30):3334-3336.
[3]吴宏林.多西紫杉醇联合消癌平注射液二线治疗晚期非小细胞肺癌的效果评价[J].中国医药指南,2016,14(15):171-172.
[4]张志华,张海冬.培美曲塞联合消癌平注射液治疗中晚期非小细胞肺癌32例临床疗效观察[J].中国医药指南,2012,10(12):553-554.
[5]赵伟.消癌平联合多西紫杉醇治疗晚期非小细胞肺癌的疗效研究[J].心理医生,2017,23(2):65-66.
[6]李心国,姜晓静.消癌平注射液联合GP方案治疗晚期非小细胞肺癌的临床观察[J].中国临床医生杂志,2016,44(10):62-64.
[7]王延涛.消癌平注射液联合GP方案治疗晚期非小细胞肺癌的临床研究[J].青岛医药卫生,2012,44(4):246-248.
[8]张丰云,李秋文,管静芝,等.消癌平注射液联合GP方案治疗晚期非小细胞肺癌疗效观察[J].肿瘤基础与临床,2011,24(5):415-417.
[9]李清林,程斌.消癌平注射液联合GP化疗方案治疗晚期非小细胞肺癌临床疗效研究[J].中华中医药学刊,2016,34(4):785-787.
[10]杨宏,吕爽,王珏,等.消癌平注射液联合NP方案治疗晚期NSCLC的临床观察[J].中国医药导报,2011,8(8):64-65.
[11]高志豪.消癌平注射液联合TC方案治疗非小细胞肺癌晚期患者的疗效观察[J].当代医学,2016,22(25):153-154.
[12]李亚莉,周恒根,倪敬忠,等.消癌平注射液联合TC方案治疗晚期非小细胞肺癌临床观察[J].现代中西医结合杂志,2015,24(3):316-318.
[13]梅朝蓉,王恳,雷娜,等.消癌平注射液联合TP方案治疗晚期非小细胞肺癌的临床观察[J].中国药房,2015,24(11):1531-1533.
[14]夏国安.消癌平注射液联合TP方案治疗晚期非小细胞肺癌临床观察[J].临床医药实践,2013,22(2):83-85.
[15]沈李伟,邱文生,兰传鑫,等.消癌平注射液联合TP化疗治疗晚期非小细胞肺癌疗效观察[J].中外医学研究,2015,13(32):8-9.
[16]刘爱芳.消癌平注射液联合化疗治疗晚期非小细胞肺癌的疗效体会[J].临床医药文献电子杂志,2016,3(22):4415-4416.
[17]方欢,王静,潘春峰,等.消癌平注射液联合化疗治疗晚期非小细胞肺癌的临床观察[J].中国医院用药评价与分析,2013,13(2):165-168.
[18]张瑞星,岳江涛,王天平,等.消癌平注射液联合化疗治疗晚期非小细胞肺癌的临床观察[J].肿瘤基础与临床,2012,25(5):438-440.
[19]姜子瑜,李灵常.消癌平注射液联合化疗治疗晚期非小细胞肺癌临床分析[J].内蒙古中医药,2017,36(23):100-101.
[20]宋宇,钱晓兰,王少开,等.消癌平注射液联合化疗治疗晚期非小细胞肺癌临床疗效评价[J].中医临床研究,2016,8(36):122-123.
[21]石磊,杨卫兵,柏玉举,等.消癌平注射液联合化疗治疗中晚期肺癌的临床分析[J].医药前沿,2015,5(26):155-156.
[22]徐建建.消癌平注射液联合化疗治疗中晚期肺癌的临床分析[J].中外医疗,2017,36(12):116-118.
[23]胡晓琳,刘喜松,陈细定.消癌平注射液联合吉西他滨和卡铂治疗ⅢB和Ⅳ期非小细胞肺癌的临床评价[J].药物评价研究,2017,40(2):262-265.
[24]朱丹.消癌平注射液联合间断化疗对老年晚期非小细胞肺癌的治疗效果观察[J].中国医药指南,2017,15(36):206-207.
[25]杨万全,王恳.消癌平注射液联合间断化疗治疗老年晚期非小细胞肺癌[J].肿瘤基础与临床,2013,26(6):495-497.
[26]瞿红英.多西紫杉醇联合消癌平注射液二线治疗晚期NSCLC的疗效观察[J].世界最新医学信息文摘,2015,15(A5):11-12.
[27]Siegel RL,Miller KD,Jemal A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
[28]石远凯,孙燕,丁翠敏,等.中国埃克替尼治疗非小细胞肺癌专家共识(2016年版)[J].中国肺癌杂志,2016,19(7):489-494.
[29]国家药典委员会.中华人民共和国药典[M].北京:中国医药科技出版社,2015:296-297.
[30]白爽,李奕诺,徐鑫,等.乌骨藤化学成分及药理活性研究进展[J].解放军药学学报,2015,31(3):260-264.
[31]杨洪枢,张科军,宋程浩,等.消癌平注射液对原发性肝癌术前患者机体免疫功能的影响[J].中华中医药学刊,2015,33(6):1438-1440.
[32]韩淑燕,郑文献,何曦冉,等.消癌平注射液联合吉非替尼对耐药非小细胞肺癌H460和H1975裸鼠移植瘤的抑制作用[J].中国药理学与毒理学杂志,2016,30(1):44-52.
[33]郑爱文,李涛,陈雅卿,等.消癌平联合顺铂对高转移人卵巢癌HO-8910PM细胞的抑制作用[J].中华肿瘤杂志,2016,38(1):11-16.
[34]王美,杜丹玉,范薇,等.消癌平注射液抗血管生成作用及其机制研究[J].药学学报,2016,51(2):309-315.
[35]王峰,樊青霞,王洪海,等.消癌平注射液联合化疗治疗中晚期食管癌的疗效和安全性[J].中华肿瘤杂志,2017,39(6):453-457.